Difference between revisions of "Beta thalassemia"
Jump to navigation
Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Section editor''' |- |s...") |
m (Text replacement - "style="background-color:#1a9851" |Phase III" to "style="background-color:#1a9851" |Phase 3") |
||
| Line 29: | Line 29: | ||
|[https://doi.org/10.1056/nejmoa1910182 Cappellini et al. 2020 (BELIEVE)] | |[https://doi.org/10.1056/nejmoa1910182 Cappellini et al. 2020 (BELIEVE)] | ||
|2016-2017 | |2016-2017 | ||
| − | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[#Placebo|Placebo]] | |[[#Placebo|Placebo]] | ||
| style="background-color:#1a9850" |Superior reduction in transfusion burden | | style="background-color:#1a9850" |Superior reduction in transfusion burden | ||
Revision as of 02:20, 16 December 2021
| Section editor | |
|---|---|
 |
Benjamin Tillman, MD Vanderbilt University Nashville, TN |
2 regimens on this page
2 variants on this page
|
All lines of therapy
Luspatercept monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Cappellini et al. 2020 (BELIEVE) | 2016-2017 | Phase 3 (E-esc) | Placebo | Superior reduction in transfusion burden |
Growth factor therapy
- Luspatercept (Reblozyl) 1 mg/kg SC once on day 1
- Dose can be increased based upon response (see paper for details)
21-day cycle for at least 16 cycles
References
- BELIEVE: Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew LP, Bee PC, Lim SM, Lu MY, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A; BELIEVE Investigators. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia. N Engl J Med. 2020 Mar 26;382(13):1219-1231. link to original article contains verified protocol PubMed NCT02604433